- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.04. | Climb Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 25.03. | Climb Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.03. | Climb Bio, Inc.: Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates | 536 | GlobeNewswire (Europe) | Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus... ► Artikel lesen | |
| 25.03. | Climb Bio, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 24.02. | Climb Bio, Inc.: Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer | 334 | GlobeNewswire (Europe) | WELLESLEY HILLS, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) announced today the appointment of Perrin Wilson, Ph.D. as Chief Business Officer. Dr. Wilson is an accomplished... ► Artikel lesen | |
| CLIMB BIO Aktie jetzt für 0€ handeln | |||||
| 10.01. | Climb Bio enters licensing deal with Mabworks for CLYM116 development | 1 | Pharmaceutical Technology | ||
| 10.01. | Climb Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 09.01. | Climb Bio, Inc.: Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy | 205 | GlobeNewswire (Europe) | Transaction Expands Climb Bio's Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases New Program is a Highly Potent, Fc-engineered anti-APRIL Monoclonal Antibody Specifically... ► Artikel lesen | |
| 19.12.24 | Climb Bio, Inc.: Climb Bio to be Added to the Nasdaq Biotechnology Index | 122 | GlobeNewswire (Europe) | WELLESLEY HILLS, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- December 19, 2024 - Climb Bio, Inc. (Nasdaq: CLYM) today announced that the company will be added to the NASDAQ Biotech Index (Nasdaq: NBI)... ► Artikel lesen | |
| 11.11.24 | Climb Bio names Douglas Williams as chair | 1 | Seeking Alpha | ||
| 11.11.24 | Climb Bio, Inc.: Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board | 1 | GlobeNewswire (USA) | ||
| 24.10.24 | Woodforest Acceptance Solutions Partners With Clym to Enhance Website Accessibility and Compliance With Consumer Privacy Regulations | 305 | ACCESS Newswire | Woodforest Acceptance Solutions Partners with Clym to Enhance Merchants' Compliance and Website Accessibility, Empowering Businesses to Navigate Digital Regulations Seamlessly THE WOODLANDS, TX / ACCESSWIRE... ► Artikel lesen | |
| 02.10.24 | Eliem Therapeutics, Inc.: Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc. | 182 | GlobeNewswire (Europe) | Name change to "Climb Bio" marks the Company's transition and focus on developing treatments for immune-mediated diseases Climb Bio will begin trading on Nasdaq under the trading symbol "CLYM" effective... ► Artikel lesen | |
| 25.09.24 | Pre-market Movers: Stitch Fix, Motorsport Games, Eliem Therapeutics, Banzai International, VS MEDIA | 813 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.35 A.M. ET).In the Green Motorsport Games Inc. (MSGM) is up over 25% at... ► Artikel lesen | |
| 14.08.24 | Eliem Therapeutics, Inc.: Eliem Therapeutics Reports Second Quarter Financial Results | 113 | GlobeNewswire (Europe) | Eliem completed the acquisition of Tenet Medicines and concurrent $120 million private placement Eliem to host an Investor Day later in the year to provide an overview of budoprutug (previously referred... ► Artikel lesen | |
| 28.06.24 | Eliem Therapeutics, Inc.: Eliem Therapeutics Announces its Addition to the Russell 2000 and Russell 3000 Indexes | 237 | GlobeNewswire (Europe) | SEATTLE and CAMBRIDGE, United Kingdom, June 28, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today that the Company will be included in the Russell 2000® Index and the... ► Artikel lesen | |
| 27.06.24 | Eliem Therapeutics, Inc.: Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement | 491 | GlobeNewswire (Europe) | Eliem to focus on advancing TNT119, an anti-CD19 antibody designed to treat a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 89,65 | -3,45 % | BioNTech, BioNxt Solutions, Merck KGaA - Chancen nach der Korrektur | Die Zahlensaison für das erste Quartal 2025 ist im Gange und aufgrund des Zollhammers des US-Präsidenten Donald Trump noch einmal spannender denn je. Vor allem die Prognosen für das weitere Geschäftsjahr... ► Artikel lesen | |
| CUREVAC | 3,036 | -3,74 % | CureVac mit EILMELDUNG: Insider kaufen massenhaft Anteile - Explodiert die Aktie jetzt komplett? | ||
| MODERNA | 24,555 | +0,41 % | Moderna, Inc Q1 Loss Decreases, Beats Estimates | WASHINGTON (dpa-AFX) - Moderna, Inc (MRNA) announced Loss for first quarter that decreased from last year and beat the Street estimates.The company's bottom line came in at -$971 million, or... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 535,40 | -0,11 % | Verlustreicher Tag für Regeneron Pharmaceuticals-Aktionäre: Aktienkurs sinkt deutlich (497,00 €) | Zu den großen Verlierern an der Börse zählt am Dienstag der Anteilsschein von Regeneron Pharmaceuticals . Das Papier verbilligt sich heute deutlich. Zu den Anteilsscheinen mit den größten Kursverlusten... ► Artikel lesen | |
| TEMPUS AI | 54,28 | -5,02 % | Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time. | ||
| QIAGEN | 38,250 | +0,91 % | Biotech Report: Qiagen behauptet, Evotec sacken ab | (shareribs.com) Frankfurt / New York 30.04.2025 - Biotech-Aktien zeigten sich im deutschen Handel überwiegend fest. Für Qiagen ging es nach oben, Biontech und Evotec gaben nach. An der Wall Street konnte... ► Artikel lesen | |
| EVOTEC | 7,480 | -1,81 % | Evotec-Aktie mit Kursgewinnen (7,568 €) | Im Plus liegt zur Stunde die Aktie von Evotec . Der jüngste Kurs betrug 7,57 Euro. Heute hat sich an der deutschen Börse das Wertpapier von Evotec zwischenzeitlich um 2,52 Prozent verteuert. Der Kurs... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 46,220 | 0,00 % | Miliarden-Deal abgeschlossen: Merck schluckt SpringWorks: Tumor-Medikament steht kurz vor der Zulassung! | © Foto: Arne Dedert/dpaMerck verstärkt das Pharmageschäft mit dem Zukauf von SpringWorks Therapeutics. Der deutsche Konzern teilte am Montag mit, das US-Biotech-Unternehmen für 47 US-Dollar je Aktie... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,755 | -16,51 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 27,720 | -0,57 % | Why Summit Therapeutics Inc. (SMMT) Soared Last Week | ||
| JANUX THERAPEUTICS | 29,840 | -9,27 % | Janux Therapeutics, Inc. (JANX): Among Unknown Billionaire Phill Gross' Stock Picks with Huge Upside Potential | ||
| ADMA BIOLOGICS | 23,680 | +0,77 % | ADMA Biologics, Inc.: ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process | Approval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity First U.S. Regulatory Approval of Innovative IG Yield Enhancement Process... ► Artikel lesen | |
| AMGEN | 247,75 | -0,38 % | Amgen-Aktie heute am Aktienmarkt gefragt (250,2786 €) | Der Anteilsschein von Amgen notiert heute ein wenig fester. Das Papier notiert zur Stunde bei 285,25 US-Dollar. Das Wertpapier von Amgen verzeichnet derzeit einen Preisanstieg von 0,71 Prozent. Es hat... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 15,460 | +1,34 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces Chief Financial Officer Transition | WESTLAKE VILLAGE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
| ARVINAS | 7,645 | -0,71 % | Pre-market Movers: Zoomcar, NanoVibronix, Arvinas, E2open Parent, TTM Technologies | NEW DELHI (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.55 A.M. ET).In the Green Zoomcar Holdings, Inc. (ZCAR) is up over 123%... ► Artikel lesen |
CLIMB BIO INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,040 (+3,15 %) liegt der Kurs bei 1,310 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CLIMB BIO INC finden Sie auf Wallstreet Online.